Phathom Pharmaceuticals (PHAT) Stock: Buy, Sell, or Hold?
PHAT - Phathom Pharmaceuticals, Inc. Common Stock
$8.36
-0.01 (-0.12%)
▼
5d:
-7.62%
30d:
-8.83%
90d:
-18.6%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Oct 29, 2026
Get Alerted When PHAT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: PHAT shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: PHAT shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$11.82
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$7.34
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PHAT is currently trading at $8.36, which is considered oversold relative to its 30-day fair value range of $8.52 to $9.33. The stock's valuation (Forward PE: 7.5) is in line with its historical norms (7.6). Remarkably, the market is currently pricing in an annual earnings decline of 0.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PHAT is in a strong downtrend. Immediate support is located at $8.07, while resistance sits at $9.73.
Market Sentiment: The stock scores a mixed 54/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $21.50 (+157.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PHAT is in a strong downtrend. Immediate support is located at $8.07, while resistance sits at $9.73.
Market Sentiment: The stock scores a mixed 54/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $21.50 (+157.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$8.52 -
$9.33
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
Protect Your Profits
Holding PHAT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (54/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 157.2% below Wall St target ($21.50)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$8.52 -
$9.33
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$8.07
Resistance Level
$9.73
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.53
Wall Street Target
$21.50
(+157.2%)
Revenue Growth (YoY)
88.0%
Profit Margin
-41.3%
Valuation Discount vs History
-0.5% cheaper
PE vs Historical
7.5 vs 7.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.5%
(market-implied from PE analysis)
1-Year Target
$8.32
(-1%)
2-Year Target
$8.28
(-1%)
3-Year Target
$8.24
(-2%)
3-Yr Target (if PE normalizes)
(PE: 8→8)
$8.31
(-1%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.5 to 7.6
Stabilization Target:
$8.43
(+0.9%)
PE Expansion Potential:
+0.9%
Share & Embed Analysis
Last updated: September 13, 2026 1:49 AM ET
Data refreshes hourly during market hours. Next update: 2:49 AM
Data refreshes hourly during market hours. Next update: 2:49 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHAT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 50 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 44 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$289 | 59 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 41 HOLD |
Advanced PHAT Option Strategies
Professional options setups generated by AI based on today's PHAT price and gamma walls.
